Pay in 4 interest-free payments of $5.08 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
Compounded versions made by FDA-registered 503B pharmacies are non-FDA-approved preparations containing the peptides semaglutide or tirzepatide, at a fraction of the cost
The glucagon-like peptide-1 (GLP-1) receptor agonist, exenatide, inhibits small intestinal motility, flow, transit and absorption of glucose in healthy subjects and patients with type 2 diabetes: a randomised controlled trial
Patient Safety Data Driving the Posture The FDAs enforcement posture is anchored in accumulated adverse event data: 455+ adverse event reports linked to compounded semaglutide as of early 2025 (current counts higher) 320+ adverse event reports linked to compounded tirzepatide as of early 2025 (current counts higher) Many reports involve dosing errors from patients self-administering incorrect amounts from multidose vials Several reports document hospitalization following severe nausea, dehydration, or pancreatitis Concerns about counterfeit products entering supply chains through online channels Cold-chain integrity issues with compounded shipments arriving warm or with inadequate temperature controls Salt-form substitution risks products containing semaglutide acetate or sodium rather than semaglutide base used in FDA-approved products These data points feature prominently in FDA communications and the Federal Register notice rationale
The most important aftercare step is consistency with the full program
